SOCIAL PHARMACOLOGY - Keluarga IKMA FKMUA 2010 | …
... Pts. should be aware that even though a medicinal product is registered as “safe and effective” by authorithies ...
... Pts. should be aware that even though a medicinal product is registered as “safe and effective” by authorithies ...
Pre-AP Chemistry: Unit 1: Test Review
... f. hypothesis g. theory h. model j. element k. compound l. mixture (homogeneous vs heterogeneous) m. physical vs chemical property n. physical vs chemical change o. Intensive vs extensive properties p. separation techniques q. decomposition r. Laws of conservation s. endothermic vs exothermic reacti ...
... f. hypothesis g. theory h. model j. element k. compound l. mixture (homogeneous vs heterogeneous) m. physical vs chemical property n. physical vs chemical change o. Intensive vs extensive properties p. separation techniques q. decomposition r. Laws of conservation s. endothermic vs exothermic reacti ...
The draft pharmaceutical policy: the weakest link
... and doctors’ pay has held steady as a percentage of overall expenditures, spending by health institutions, which includes professionals’ salaries, is still experiencing cutbacks. The government’s overall capacity is unchanged, for the three plans are like sections of one wallet: taking more money ou ...
... and doctors’ pay has held steady as a percentage of overall expenditures, spending by health institutions, which includes professionals’ salaries, is still experiencing cutbacks. The government’s overall capacity is unchanged, for the three plans are like sections of one wallet: taking more money ou ...
6.2 notes
... – Synthesized in labs rather than found in nature – Quick tolerance and dependence – Amphetamine psychosis • Causes user to become delusional ...
... – Synthesized in labs rather than found in nature – Quick tolerance and dependence – Amphetamine psychosis • Causes user to become delusional ...
Review Questions on Basic Pharmacology
... Review Questions on Basic Pharmacology. Make a list of your answers & then check them against the Answer Key 1. An antagonist is a type of drug that: A.has maximal efficacy B.has affinity for a receptor but little efficacy C.binds to a receptor and activates it D.has efficacy but low affinity E.decr ...
... Review Questions on Basic Pharmacology. Make a list of your answers & then check them against the Answer Key 1. An antagonist is a type of drug that: A.has maximal efficacy B.has affinity for a receptor but little efficacy C.binds to a receptor and activates it D.has efficacy but low affinity E.decr ...
15. Dynamic combinatorial chemistry
... number of possible sequences containing X members = NX number of coupling steps required using split/pool/mix = N x X ...
... number of possible sequences containing X members = NX number of coupling steps required using split/pool/mix = N x X ...
What are Drugs? - Noadswood Science
... their fingers and toes • The worst affected now face amputation of their fingers and toes • Several face a health risk of cancer ...
... their fingers and toes • The worst affected now face amputation of their fingers and toes • Several face a health risk of cancer ...
Drug Forms
... their prescribed drugs accurately only 50% of the time. Researchers have tried to improve this percentage by inventing new drug forms. Some new ideas on the horizon is an artificial tooth that can be programmed to disperse a drug at specific times. ...
... their prescribed drugs accurately only 50% of the time. Researchers have tried to improve this percentage by inventing new drug forms. Some new ideas on the horizon is an artificial tooth that can be programmed to disperse a drug at specific times. ...
Absorption of drug
... substance that is ionized at a given pH. In the stomach, drugs that are weak acids (such as aspirin) will be present mainly in their non-ionic form, and weak bases will be in their ionic form. Since non-ionic species diffuse more readily through cell membranes, weak acids will have a higher absorpti ...
... substance that is ionized at a given pH. In the stomach, drugs that are weak acids (such as aspirin) will be present mainly in their non-ionic form, and weak bases will be in their ionic form. Since non-ionic species diffuse more readily through cell membranes, weak acids will have a higher absorpti ...
Psychopharm Study Guide
... 18. Fluoxetine facilitates an increase of 5-HT in the synapse. Enzymes are often “too busy” breaking down this excess indolamine to adequately metabolize other neurotransmitters or exogenous substances. This kind of interaction is called: ...
... 18. Fluoxetine facilitates an increase of 5-HT in the synapse. Enzymes are often “too busy” breaking down this excess indolamine to adequately metabolize other neurotransmitters or exogenous substances. This kind of interaction is called: ...
Physicochemical Properties - Near East University Docs
... new and better drugs through organic synthesis, analytical study and some physical characterization. It involves organic synthesis, complete analytical characterization including spectroscopy, identification of physical and chemical properties, computational analysis, combinatorial approach etc. 9 S ...
... new and better drugs through organic synthesis, analytical study and some physical characterization. It involves organic synthesis, complete analytical characterization including spectroscopy, identification of physical and chemical properties, computational analysis, combinatorial approach etc. 9 S ...
16-pharmacologyppt3005
... body. Molecular pharmacology: Study of the intraction of drugs such as DNA, RNA, enzymes. Chemotherapy: Treatment that destroy microorganism, paracytes, or malignant cells. Toxicology: Study of the harmful effect of drugs and chemicals. A toxicologist is also interested in finding proper antidotes t ...
... body. Molecular pharmacology: Study of the intraction of drugs such as DNA, RNA, enzymes. Chemotherapy: Treatment that destroy microorganism, paracytes, or malignant cells. Toxicology: Study of the harmful effect of drugs and chemicals. A toxicologist is also interested in finding proper antidotes t ...
Synthesis and Aggregation Behavior of Pluronic F87/Poly(acrylic acid) Block Copolymer with Doxorubicin
... produce a novel muco-adhesive block copolymer PAA80-b-F87-b-PAA80. It was observed that PAA80F87-PAA80 forms stable complexes with weakly basic anti-cancer drug, Doxorubicin. Thermodynamic changes due to the drug binding to the copolymer were assessed at different pH by isothermal titration calorime ...
... produce a novel muco-adhesive block copolymer PAA80-b-F87-b-PAA80. It was observed that PAA80F87-PAA80 forms stable complexes with weakly basic anti-cancer drug, Doxorubicin. Thermodynamic changes due to the drug binding to the copolymer were assessed at different pH by isothermal titration calorime ...
What is in a name
... Classification: - no homogenous way / system of classifying drugs that suits the purpose of every user. banyak tergantung kepada sipengguna; - clinicians - pharmacologists - medicinal chemists ...
... Classification: - no homogenous way / system of classifying drugs that suits the purpose of every user. banyak tergantung kepada sipengguna; - clinicians - pharmacologists - medicinal chemists ...
DavidsonX – D001x – Medicinal Chemistry Chapter 1
... By the early 1900s, the pharmaceutical industry had become a dynamic business. In addition to the historical herbal remedies that had been passed down through generations, advances in organic chemistry were making a broad range of synthetic drugs available. Furthermore, the formulation of the drug, ...
... By the early 1900s, the pharmaceutical industry had become a dynamic business. In addition to the historical herbal remedies that had been passed down through generations, advances in organic chemistry were making a broad range of synthetic drugs available. Furthermore, the formulation of the drug, ...
Amino acid provides shortcut to drugs
... The method might prove useful in full-scale drug production, not only because of its simplicity but because it avoids expensive and toxic metal catalysts. “From an industrial perspective Aggarwal’s process is promising, and a remarkable lead,” says process chemist Rob Singer, who works at Pfizer Wor ...
... The method might prove useful in full-scale drug production, not only because of its simplicity but because it avoids expensive and toxic metal catalysts. “From an industrial perspective Aggarwal’s process is promising, and a remarkable lead,” says process chemist Rob Singer, who works at Pfizer Wor ...
7
... Ganley, coded as AMDl in Docket No. 98N-0337. That letter was in response to the Division of OTC Drug Products’ letter of August 28,200O concerning an Application for Exemption for BC Analgesic Powder (two doses). My call was returned by Michelle Butler, Esquire. I informed Ms. Butler that we would ...
... Ganley, coded as AMDl in Docket No. 98N-0337. That letter was in response to the Division of OTC Drug Products’ letter of August 28,200O concerning an Application for Exemption for BC Analgesic Powder (two doses). My call was returned by Michelle Butler, Esquire. I informed Ms. Butler that we would ...
New Approaches to Filling the Gap in Tuberculosis Drug Discovery
... and retaining them in competition with industry. Moreover, to invest in medicinal chemistry for the public sector without the other technologies, resources, and expertise that go into drug development might result in limited success or strategic failure. An alternative could be for governments to cr ...
... and retaining them in competition with industry. Moreover, to invest in medicinal chemistry for the public sector without the other technologies, resources, and expertise that go into drug development might result in limited success or strategic failure. An alternative could be for governments to cr ...
Paul T. Sprieser, DC, DIBAK
... placebo, Benlysta was only 43.2 percent effective, compared to 33.8 percent with the placebo. The statistical method know as number needed to be treated or (NNT), if we give the drug to 11 lupus patients one might feel some benefit. The other problem is the cost for this treatment, which is given by ...
... placebo, Benlysta was only 43.2 percent effective, compared to 33.8 percent with the placebo. The statistical method know as number needed to be treated or (NNT), if we give the drug to 11 lupus patients one might feel some benefit. The other problem is the cost for this treatment, which is given by ...
Targeting the organism: present and future
... • Shorter duration: – Bactericidal and sterilizing regimen: Targets that are collectively essential to all sub-populations of bacteria residing in environments and metabolic states found during infection ...
... • Shorter duration: – Bactericidal and sterilizing regimen: Targets that are collectively essential to all sub-populations of bacteria residing in environments and metabolic states found during infection ...
Overview on Drug Delivery System
... In the recent years the researchers in the pharmaceutical and industries develop a more sophisticated and potent drugs. Most of these drugs mainly consist of protein and/ or DNA, these drugs characterize by their ability to liberate their bioactive ingredients at the right time, site and in safe con ...
... In the recent years the researchers in the pharmaceutical and industries develop a more sophisticated and potent drugs. Most of these drugs mainly consist of protein and/ or DNA, these drugs characterize by their ability to liberate their bioactive ingredients at the right time, site and in safe con ...
Pharmacology introduction
... Essential medicines, as defined by the WHO are "those drugs that satisfy the health care needs of the majority of the population; they should therefore be available at all times in adequate amounts and in appropriate dosage forms, at a price the community can afford." ...
... Essential medicines, as defined by the WHO are "those drugs that satisfy the health care needs of the majority of the population; they should therefore be available at all times in adequate amounts and in appropriate dosage forms, at a price the community can afford." ...
Slides for Chapter 6a
... HIV-1 Protease complexed with the inhibitor Crixivan (RED) made by Merck ...
... HIV-1 Protease complexed with the inhibitor Crixivan (RED) made by Merck ...
Drug discovery
In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered. Historically, drugs were discovered through identifying the active ingredient from traditional remedies or by serendipitous discovery. Later chemical libraries of synthetic small molecules, natural products or extracts were screened in intact cells or whole organisms to identify substances that have a desirable therapeutic effect in a process known as classical pharmacology. Since sequencing of the human genome which allowed rapid cloning and synthesis of large quantities of purified proteins, it has become common practice to use high throughput screening of large compounds libraries against isolated biological targets which are hypothesized to be disease modifying in a process known as reverse pharmacology. Hits from these screens are then tested in cells and then in animals for efficacy.Modern drug discovery involves the identification of screening hits, medicinal chemistry and optimization of those hits to increase the affinity, selectivity (to reduce the potential of side effects), efficacy/potency, metabolic stability (to increase the half-life), and oral bioavailability. Once a compound that fulfills all of these requirements has been identified, it will begin the process of drug development prior to clinical trials. One or more of these steps may, but not necessarily, involve computer-aided drug design. Modern drug discovery is thus usually a capital-intensive process that involves large investments by pharmaceutical industry corporations as well as national governments (who provide grants and loan guarantees). Despite advances in technology and understanding of biological systems, drug discovery is still a lengthy, ""expensive, difficult, and inefficient process"" with low rate of new therapeutic discovery. In 2010, the research and development cost of each new molecular entity (NME) was approximately US$1.8 billion. Drug discovery is done by pharmaceutical companies, with research assistance from universities. The ""final product"" of drug discovery is a patent on the potential drug. The drug requires very expensive Phase I, II and III clinical trials, and most of them fail. Small companies have a critical role, often then selling the rights to larger companies that have the resources to run the clinical trials.Discovering drugs that may be a commercial success, or a public health success, involves a complex interaction between investors, industry, academia, patent laws, regulatory exclusivity, marketing and the need to balance secrecy with communication. Meanwhile, for disorders whose rarity means that no large commercial success or public health effect can be expected, the orphan drug funding process ensures that people who experience those disorders can have some hope of pharmacotherapeutic advances.